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SUMMARY
HLA-B*46:01 was formed by an intergenic mini-con-
version, between HLA-B*15:01 and HLA-C*01:02, in
Southeast Asia during the last 50,000 years, and it
has since become the most common HLA-B allele
in the region. A functional effect of the mini-conver-
sion was introduction of the C1 epitope into
HLA-B*46:01, making it an exceptional HLA-B allo-
type that is recognized by the C1-specific natural
killer (NK) cell receptor KIR2DL3. High-resolution
mass spectrometry showed that HLA-B*46:01 has a
low-diversity peptidome that is distinct from those
of its parents. A minority (21%) of HLA-B*46:01 pep-
tides, with common C-terminal characteristics, form
ligands for KIR2DL3. The HLA-B*46:01 peptidome
is predicted to be enriched for peptide antigens
derived from Mycobacterium leprae. Overall, the re-
sults indicate that the distinctive peptidome and
functions of HLA-B*46:01 provide carriers with resis-
tance to leprosy, which drove its rapid rise in fre-
quency in Southeast Asia.
INTRODUCTION
Population expansion, cultural changes, and migration during
the last 100,000 years exposed humans to pathogens against
which they had not evolved effective resistance. Host genetics
strongly influence susceptibility to infectious disease, with path-
ogens that affect reproductive fitness imposing selection on
genes that impact disease outcomes (Karlsson et al., 2014).
Nowhere in the human genome are these effects more evident
than in the HLA region (Parham, 2005). Because of their vital
role in providing immunity against diverse and rapidly evolving
pathogens, the HLA-A, -B, and -C genes have been subject to
strong balancing selection, making them the most diverse of hu-
man genes (Barreiro and Quintana-Murci, 2010; Trowsdale,
2011). HLA-A, -B, and -C arose by a series of gene duplications
from a common ancestral MHC class I gene (Parham et al.,
1995). These genes also serve as a reservoir of polymorphic se-
quences that can be recombined to create new HLA alleles that
can provide protection against emerging pathogens. Although
such new variants are thought to arise in human populations dur-
ing episodes of Darwinian selection, there is little direct evidence
for the nature of the process. HLA-B*46:01 provides a compel-
ling example of such an episode.
HLA-B*46:01 has restricted distribution in Southeast Asia
where it likely originated around the time of the arrival of modern
humans 50,000 years ago (Abi-Rached et al., 2010; Gonza´lez-
Galarza et al., 2015). It most likely rose in frequency following a
selective sweep of the type more often seen in small, isolated
populations (Abi-Rached et al., 2010), and it is now carried by
110 million individuals of Southeast Asian descent (Gonza´lez-
Galarza et al., 2015). Despite its high frequency, HLA-B*46:01
is an unusual allele, formed by the recombination between
HLA-B*15:01 andHLA-C*01:02. Similar intergenic recombinants
have been identified (Hildebrand et al., 1992; Steiner et al., 2002),
but none is found at comparable frequency, suggesting that
HLA-B*46:01 fills an immunological niche not afforded by either
parent or any other HLA class I variant found in the region.
Supporting this notion, epidemiologic studies suggest that
HLA-B*46:01may confer protection againstMycobacterium lep-
rae, the causative agent of leprosy, which is endemic to South-
east Asia (Wang et al., 1999).
HLA class I glycoproteins are found on virtually all human cells,
where they act as ligands for the killer-cell immunoglobulin-like
receptors (KIRs) of natural killer (NK) cells and the T cell recep-
tors (TCRs) of cytotoxic CD8 T cells (Colonna and Samaridis,
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1995; Zinkernagel and Doherty, 1974). A key feature of HLA
class I is a short peptide, produced by intracellular protein degra-
dation, that is bound during assembly of the HLA in the endo-
plasmic reticulum. KIRs and TCRs recognize the upper face of
HLA and its bound peptide (Boyington et al., 2000; Fan et al.,
2001; Garboczi et al., 1996). TCR recognition is exquisitely sen-
sitive to the sequence of the bound peptide. KIR binding appears
less so, though the rules that govern the peptide specificity of
KIR have yet to be fully defined.
Structural, functional, and genetic studies of HLA class I and
its counterparts in non-human primates support a model in
which HLA-A and -B evolved to become the major TCR ligands,
whereas HLA-C evolved the C1 and C2 epitopes to become the
principal KIR ligands (Guethlein et al., 2015). In this context,
HLA-B*46:01 is an exceptional allotype that carries the C1
epitope and functions as a KIR ligand (Barber et al., 1996; Zem-
mour et al., 1992). As part of their functional specialization,
HLA-A, -B, and -C bind distinctive sets of peptides and are
distinguished by locus-specific polymorphisms and differences
in cell-surface expression (McCutcheon et al., 1995; Sibilio
et al., 2008; Turner et al., 1998; Zemmour and Parham, 1992).
HLA-B*46:01 differs from HLA-B*15:01 at residues 66–76 of
the a1 helix that derive from HLA-C*01:02 (Zemmour et al.,
1992). Within this 11-residue segment, HLA-B*46:01 differs
from HLA-B*15:01 at seven positions (K66I, Y67S, R69T,
Q70N, A71T, D74Y, and V76E). Val76 is essential for the C1
epitope (Barber et al., 1996; Biassoni et al., 1995), and the
KYRV motif at positions 66, 67, 69, and 76 reduces cell-surface
expression of HLA-B*46:01 (Sibilio et al., 2008). Contributing to
the TCR- and KIR-binding sites are residues 66, 69, 70, 71, 74,
and 76 (Boyington et al., 2000; Fan et al., 2001; Garboczi et al.,
1996). Because residues 66–76 comprise half of the polymorphic
positions in the binding groove, they are predicted to influence
the peptide-binding specificity of HLA-B*46:01.
Prior to this study, knowledge of the HLA-B*46:01 peptidome
was limited to six peptides (Barber et al., 1996). Here we define at
high resolution the peptidomes of HLA-B*46:01 and its parents.
We then identify those peptides that provide ligands for the
C1-specific NK cell receptor, KIR2DL3. Comparison of >6,000
HLA-B*15:01-binding peptides, >2,000 HLA-B*46:01-binding
peptides, and >750 HLA-C*01:02-binding peptides shows how
the recombination that created HLA-B*46:01 gave it a pepti-
dome that is completely different from that of its parents. Its
distinctive peptide-binding site appears well suited to bind anti-
genic peptides derived from M. leprae.
RESULTS
HLA-B*46:01, HLA-B*15:01, and HLA-C*01:02 Have
Distinctive Peptidomes
To compare the peptides bound byHLA-B*46:01 and its parental
allotypes, we isolated these HLA molecules, eluted the bound
peptides, and determined their sequences by mass spectrom-
etry. We identified 6,387 peptides for HLA-B*15:01, 788 for
HLA-C*01:02, and 2,115 for HLA-B*46:01 (Figure 1A). This is
consistent with previous reports showing that HLA-C peptide
repertoires are generally smaller and less diverse than those of
HLA-A and -B (Neisig et al., 1998; Rasmussen et al., 2014).
The intermediate size of the HLA-B*46:01 peptidome is consis-
tent with its binding site being a hybrid of the parental allotypes.
A majority (84.2%) of the peptides characterized is specific for
one of the three HLAs, while only 15.8% bind to two of the three
HLA class I molecules, and only one peptide, TSSYKPIV, binds
all three (Figure 1A; Figure S1). Consistent with the similarity of
their primary structures, theHLA-B*15:01 andHLA-B*46:01 pep-
tidomes have the greatest overlap, with 333 shared peptides
(Figure 1B). Although the sequences of the peptide-binding do-
mains of HLA-B*15:01 and HLA-B*46:01 differ only by 3.8%,
their peptidomes differ by >84%.
Consistent with their gene-specific polymorphisms (Turner
et al., 1998; Zemmour and Parham, 1992), the peptide-binding
domains of HLA-B*15:01 and HLA-C*01:02 differ by 14.4%,
and these allotypes have only three peptides in common (Fig-
ure 1B). The peptide-binding domains of HLA-C*01:02 and
HLA-B*46:01 differ by 10.6%, and these allotypes have 19
common peptides. Thus, the gene conversion that created
HLA-B*46:01 gave it a new and distinctive peptidome.
The HLA-B*46:01 Peptidome Is Skewed toward
Nonamer Peptides
We identified differences in the lengths of peptides bound by
each allotype (Figure 1C). HLA-B*15:01-binding peptides exhibit
a wide range in length: a minority (44%) are nonamer peptides
and30% are longer than decamers (Figure 1D). With a majority
(54%) of HLA-C*01:02-binding peptides being nonamers, their
range is narrower than those of HLA-B*15:01 (Figure 1D, upper
panel). HLA-B*46:01-binding peptides have the narrowest
range, with >80% of them being nonamers or decamers (Fig-
ure 1D, upper panel). Among the 333 peptides shared by
HLA-B*15:01 and B*46:01, 75% are nonamers (Figure 1D,
lower panel; Figure S1). Thus, the skewing of HLA-B*46:01 pep-
tides for nonamers is more pronounced in peptides also bound
by HLA-B*15:01. This contrasts with those shared with
HLA-C*01:02, of which only 37% are nonamers (Figure 1D, lower
panel). Thus, HLA-B*46:01 has a peptide-binding site with stron-
ger selectivity for nonamer peptides than either parent.
HLA-B*46:01 Incorporates Elements from Both Parents
in Its Peptide-Binding Motif
Wenext identified the amino acid preference of each peptidome.
Peptides bound by HLA-B*15:01 and HLA-B*46:01 usually have
Tyr, Phe, Leu, or Met at P9, and they share a similar, though less
conserved, preference for Lys or Ile at P3. These properties are
consistent with HLA-B*15:01 andHLA-B*46:01 having sequence
identity in the F and D pockets that bind P9 and P3, respectively
(Figure S1E).
By contrast, at P2, HLA-B*15:01 and HLA-B*46:01 have diver-
gent preferences. Although both bind peptides with Leu at P2,
Gln is abundant in HLA-B*15:01 peptides (26%) whereas Ala is
most common in HLA-B*46:01 peptides (28%) (Figure 2A). Like
HLA-B*46:01, HLA-C*01:02 binds peptides with Ala and Leu at
P2 (32% and 17%, respectively), as well as peptides with Ser
at P2 (20%). Thus, all three allotypes commonly bind peptides
with Leu at P2, the most common amino acid in peptides bound
by HLA-B*15:01, but not in those bound by HLA-B*46:01 or
HLA-C*01:02 where Ala predominates. These results correlate
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with the sequences at positions 66–70 of the B pocket, which are
identical in HLA-C*01:02 and HLA-B*46:01, but not in
HLA-B*15:01 (Figure S1E). HLA-B*46:01 and HLA-C*01:02 share
a common motif (Glu, Ala, or Ser) at position 8. This is an unex-
pected finding as the HLA backbone places limited constraint on
P8 (Boyington et al., 2000). One possibility is that Val76, a residue
shared by HLA-B*46:01 and HLA-C*01:02, mediates this effect.
HLA-B*46:01 also acquired new properties in peptide selection.
This is most evident at P1 where Phe and Tyr are common, but
not in either parent (Figure 2A). The HLA*C*01:02 motif is
different from the four broad motifs described for HLA-C (Ras-
mussen et al., 2014), in having Pro at P3 and Leu at P9 in
>85% of its peptides.
Subsets of HLA-B*46:01-Binding Peptides Resemble
HLA-B*15:01- or HLA-C*01:02-Binding Peptides
A covariation matrix was used to identify conserved pairs of
amino acids in nonamer peptides bound by each allotype
(Figure 2B). In the peptides bound by HLA-B*15:01 and
HLA-B*46:01, pairs of residues at P2 and P9 are conserved.
The most common motif observed in HLA-B*15:01 (35%) and
HLA-B*46:01 (30%) peptides combines Leu at P2 with Tyr at
P9. Both allotypes have a second, less common motif: Gln at
P2 with Leu at P9 in HLA-B*15:01 and Ala at P2 with Leu at P9
in HLA-B*46:01 (Figure S2). For HLA-C*01:02 peptides, pairs of
residues at P2 and P3 and at P3 and P9 are conserved. These
peptides combine Ala at P2 with Pro at P3 and Pro at P3 with
Leu at P9 (Figure S2C). Reflecting its hybrid structure,
HLA-B*46:01- and HLA-B*15:01-binding peptides share the
Leu2/Tyr9 9 pair of residues, whereas the HLA-B*46:01- and
HLA-C*01:02-binding peptides share the Ala2/Leu9 pair of resi-
dues. Covariation between pairs of amino acid residues in pep-
tides bound by MHC has been previously observed (Birnbaum
et al., 2014), with structural analyses indicating it occurs due to
alterations in the register of the peptide backbone, causing
compensatory changes along the peptide-MHC interface (Chap-
pell et al., 2015; Fremont et al., 1995; Koch et al., 2007).
Extending this analysis, we relaxed the requirement for
conserved pairs of identical amino acids, and we compared
the biochemical properties of each peptidome by principal-
component analysis (PCA) (Figure 2C). The HLA-B*15:01 pepti-
dome forms a single dominant cluster, contrasting with a small
tight cluster formed by that of HLA-C*01:02. There is little spatial
overlap between these peptidomes, indicating that they contain
biochemically distinct peptides. The HLA-B*46:01 peptidome is
more diffuse, resembling a fusion of the two parents. The larger
cluster overlaps with that of HLA-B*15:01, the smaller one with
HLA-C*01:02. These results are consistent with the covariation
analysis (Figure 2B; Figure S2), and they show that
HLA-B*46:01 presents two subsets of peptides that are bio-
chemically similar, but not identical, to those of its parents.
A Minority of HLA-B*46:01 and HLA-C*01:02 Peptides
Are Strong KIR2DL3 Ligands
HLA-B*46:01 and HLA-C*01:02, but not HLA-B*15:01, carry the
C1 epitope and are recognized by KIR2DL3 (Moesta et al., 2008).
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Figure 1. HLA-B*46:01, HLA-B*15:01, and HLA-C*01:02 Have Distinctive Peptidomes
(A) Venn diagram showing each peptidome represented by a color-shaded circle: HLA-B*15:01 (red), HLA-C*01:02 (blue), and HLA-B*46:01 (orange). The area of
the circle is proportional to the number of distinct peptides (number shown in center of circle). The area of each circle overlap is proportional to the number of
shared peptides (number shown within or beside each overlap) that bind to the two allotypes.
(B) Listed are the total number of peptides bound by HLA-B*15:01 (red), HLA-C*01:02 (blue), or HLA-B*46:01 (orange); the proportion bound by only that allotype
(% distinct); as well as the proportion shared by pairs of allotypes (% shared with).
(C) For each allotype the histogram divides the binding peptides according to length, given as the number of amino acid residues.
(D) The proportion of peptides (%) that bind to one allotype (upper panel) or are shared by two allotypes (lower panel) plotted according to their length. The
peptides shared by HLA-B*15:01 and HLA-C*01:02 are not plotted because they are too few.
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To determine if KIR2DL3 displays a preference for specific pep-
tide combinations, we incubated KIR2DL3-coated beads with
sHLA, isolated the bound peptides, and determined their se-
quences by mass spectrometry. We call these peptides KIR
permissive, as they enable the HLA molecule to be recognized
by KIR2DL3.
No KIR-permissive peptides were isolated from HLA-B*15:01.
By contrast, six KIR-permissive peptides were eluted from
HLA-C*01:02 and 38 from HLA-B*46:01 (Figure S3). These pep-
tides comprise 7% and 21% of the total number of peptides
identified for HLA-C*01:02 and HLA-B*46:01, respectively (Fig-
ure 3A). For both allotypes, the proportion of nonamers was
greater in KIR-permissive peptides (Figure 3B). That a higher
proportion of HLA-B*46:01-binding peptides are KIR permissive
is consistent with binding assays showing that HLA-B*46:01 has
a higher affinity for KIR2DL3 than HLA-C*01:02 (Hilton et al.,
2012, 2015a, 2015b; Moesta et al., 2008).
The sequences of the KIR-permissive and non-permissive
nonamer peptides bound by HLA-B*46:01 were compared (Fig-
ure 3C). (The low number of KIR-permissive peptides identified
precluded similar analysis of HLA-C*01:02.) KIR-permissive
peptides have significantly increased frequency of Asn at P3
and Ser at P7 and decreased frequency of Glu at P7 and P8 (Fig-
ure 3D, upper panel). Analysis of the concatenated biochemical
properties of peptides in each group showed significant differ-
ences only at the C terminus of the peptide (positions 7–9)
B
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Figure 2. HLA-B*46:01 Binds a Subset of Peptides with a Distinctive Amino Acid Motif and Biochemical Properties
(A) Kullback-Leibler sequence logos showing amino acid preferences for nonamer peptides bound byHLA-B*15:01 (left), HLA-B*46:01 (center), andHLA-C*01:02
(right). Each logo consists of stacks of amino acid symbols, one stack for each position in the sequence. The total height of the column of amino acids represents
the level of conservation at that position, and the residue height denotes its relative frequency. The colors of each amino acid correspond to their biochemical
characteristics: acidic (red), basic (blue), hydrophobic (black), and polar (green). Sequence logos were generated using WebLogo (Crooks et al., 2004).
(B) Covariation matrices for nonamer peptides bound by each allotype. The color of each square represents the conservation at or covariation between the listed
residues on a heatmap scale, with blue indicating weak covariation and red indicating strong covariation.
(C) PCA density plots show the distribution of nonamer peptides bound by HLA-B*15:01 (left, red), HLA-B*46:01 (center, orange), and HLA-C*01:02 (right, blue).
For comparison, in each plot the distribution of nonamer peptides from the other allotypes is shown in gray. The percentage of the variation in the dataset shown
by the first (PC1) and second (PC2) principal components is listed to the left.
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(Figure 3D, lower panel). Here, KIR-permissive peptides are
significantly more likely to have small, positively charged, and
hydrophobic amino acids.
KIR2DL3-Permissive Peptides Inhibit NK Cell
Cytotoxicity
Wenext tested the capacity of KIR-permissive peptides to inhibit
degranulation of NK cells. Donor-derived KIR2DL3+ NK cells
were tested for inhibition after incubation with TAP-deficient
T2 cells (which naturally express HLA-C*01:02) loaded with
selected peptides. Wild-type T2 cells with no exogenous peptide
expressed low levels of HLA-C*01:02 (Figure 3E). KIR2DL3-ex-
pressing NK cells degranulated strongly when challenged with
wild-type T2 cells (Figure 3F). Pulsing T2 cells with three
HLA-C*01:02-specific peptides (two KIR permissive and one
non-permissive) stabilized HLA-C*01:02 expression to a
similar extent (Figure 3E). The HLA-B*46:01-specific peptide
YANDFASEY stabilized HLA-C*01:02 expression but to a lesser
degree (Figure 3E). Both KIR-permissive peptides significantly
inhibited NK cell degranulation but to different degrees (Fig-
ure 3F). Consistent with their relative affinity for KIR2DL3 (Fig-
ure S3C), AAPLRLIAA (the higher affinity peptide) inhibited NK
cell degranulation more than IAPTGHSL (Figure 3F). The non-
permissive and HLA-B*46:01-specific peptides did not inhibit
NK cell cytotoxicity (Figure 3F).
HLA-B*46:01 Has a Less Diverse Peptidome Than
HLA-B*15:01
We performed two analyses to compare the diversity of each
HLA peptidome. The relative sequence similarity of the amino
acids in each peptidome was determined by calculating the
per-position divergence in amino acid composition in five
randomly selected sets of nonamer peptides. Consistent with
previous studies of HLA-B and -C (Neisig et al., 1998; Rasmus-
sen et al., 2014) and our analysis of the raw number of distinct
peptides in each peptidome (Figure 1A), we found that the
HLA-B*15:01 and HLA-C*01:02 peptidomes had the least and
most sequence similarity, respectively, with the HLA-B*46:01
peptidome having intermediate sequence similarity (Figure 4A).
The true diversity of each peptidome was determined by
comparing the abundance (intensity) of their bound peptides,
as assessed by mass spectrometry. To control for the
A
B
C D E
F
Figure 3. KIR2DL3 Recognition of HLA-B*46:01 and HLA-C*01:02 Is Peptide Dependent
(A) Pie charts showing the number and percentage of KIR2DL3-permissive peptides bound by HLA-C*01:02 (left, blue) and HLA-B*46:01 (right, orange) relative to
non-permissive peptides (gray).
(B) The percentage of HLA-C*01:02 (blue, upper panel) and HLA-B*46:01 (orange, lower panel) peptides that are KIR permissive or non-permissive (gray) divided
by length.
(C) Kullback-Leibler sequence logos representing the amino acid preferences for nonamer HLA-B*46:01 KIR-permissive (top panel) and non-permissive (bottom
panel) peptides. The colors of each amino acid correspond to their biochemical characteristics: acidic (red), basic (blue), hydrophobic (black), and polar (green).
Sequence logos were generated using WebLogo (Crooks et al., 2004).
(D) Heatmapmatrix showing the log10 p values comparing the frequency of amino acids (top panel, Fisher’s exact tests) and concatenated amino acid properties
(bottom panel, two-sample t tests) between KIR-permissive and non-permissive peptides bound by HLA-B*46:01. Increases in the frequency of an amino acid or
the value of a biochemical property are shown in red, decreases in blue. Amino acids or properties that differ significantly between the groups are outlined in
black.
(E) Stabilization of HLA-C*01:02 expression on T2 cells as determined by DT9 staining (MFI shown on x axis) in the absence of peptide (wild-type) or with selected
peptides pulsed at 100 mM and measured by flow cytometry. For (E) and (F), HLA allotype specificity and KIR2DL3 reactivity are indicated in the key.
(F) Degranulation of donor-derived KIR2DL3+ NK cells incubated with T2 cells as determined by percentage CD107a expression in the absence of peptide (wild-
type) or with selected peptides pulsed at 100 mM and measured by flow cytometry (bars represent mean ± SD). Horizontal lines indicate conditions in which
degranulation differs significantly from wild-type (one-way ANOVA with multiple comparisons, *p < 0.05 and ***p% 0.001).
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ionization potential of individual peptides, we only compared the
distribution of the peptidomes. For HLA-B*15:01, HLA-C*01:02,
and HLA-B*46:01, the ten most abundant peptides contribute
18%, 34%, and 37%, respectively, to the total peptide mass
(Figure 4B; Figure S4). We next calculated the smallest
number of peptides that account for 50% of the bound peptide
mass. This number is 95 for HLA-B*15:01, 20 for HLA-C*01:02
and 20 for HLA-B*46:01 (Figure 4C; Figure S4). Thus, the
HLA-B*15:01 peptidome has approximately five times the
diversity of the HLA-C*01:02 and HLA-B*46:01 peptidomes.
Calculation of diversity indices for each peptidome showed
that HLA-B*15:01 is most diverse, followed by HLA-C*01:02
and then HLA-B*46:01 (Figure 4C). Together, these results
show that HLA-B*46:01 has a smaller peptide repertoire that is
less diverse in length, abundance, and amino acid content
than itsmore closely related parent, and they highlight the forma-
tive effect of residues 66–76.
A Predictive Model Indicates that HLA-B*46:01 Differs
from HLA-B*15:01 in Its Capacity to Bind Pathogen-
Derived Peptides
HLA class I peptidomes with low diversity are thought to provide
protection against one or a number of closely related pathogens
(Chappell et al., 2015). Epidemiologic studies suggest that the
HLA-B*46:01-MICA-A5 haplotype protects against development
of lepromatous leprosy, the fulminant form of disease caused by
M. leprae (Wang et al., 1999). Leprosy is endemic to Southeast
Asia, where HLA-B*46:01 is found at high frequency (Figures
5A and 5B) (Gonza´lez-Galarza et al., 2015). We hypothesized
that HLA-B*46:01might be better adapted to present peptide an-
tigens derived fromM. leprae than one or both of its parents. To
assess this possibility, we identified 22 antigenic M. leprae pro-
teins (Wiker et al., 2011), and we used a nine-amino acid-sliding
window to create a library of all possible nonamer peptides. Their
binding to each allotype was predicted using NetMHC 4.0 (re-
trained to include data from this study) (Nielsen et al., 2003).
In support of our hypothesis, HLA-B*46:01 is predicted to
bind a significantly higher number ofM. leprae-derived peptides
than HLA-B*15:01 (Figure 5C; Figure S5). HLA-C*01:02 also pre-
sents a higher number of M. leprae-derived peptides, although
the difference is not significant. Similarly, both HLA-B*46:01
and HLA-C*01:02 are predicted to bind a significantly higher
number of Mycobacterium tuberculosis-derived peptides than
HLA-B*15:01 (Figure 5C). By contrast, HLA-B*46:01 binds equal
or lower numbers of peptides derived from Salmonella Enteriti-
dis, HIV-1, or H1N1-influenza as compared to its parents (Fig-
ure 5D). This decrease is significant for HIV-1-derived peptides
(Figure 5C).
We compared the distribution of the M. leprae-derived pep-
tides predicted to bind HLA-B*46:01 to the distribution of the
empirically determined peptides (shown in Figure 2C, center
panel). To assess their relative similarity to the HLA-C*01:02-
like and HLA-B*15:01-like peptides, we used k-nearest neighbor
clustering to define two discontinuous subsets. When divided in
this way, 15% of HLA-B*46:01 peptides fall in HLA-C*01:02-like
cluster 1 and 85% of peptides fall in HLA-B*15:01-like cluster 2
(Figure 5E, top panel). Comparison with M. leprae-derived pep-
tides predicted to bind HLA-B*46:01 shows a significantly higher
percentage (25%) fall in HLA-C*01:02-like cluster 1 (Figure 5E).
This shift to the C*01:02-like cluster 1 is also noted in KIR-
permissive peptides that are more than twice as likely to fall in
cluster 1 (33%) as compared to the wider HLA-B*46:01 pepti-
dome. Together these results suggest that HLA-B*46:01 may
provide protection against lepromatous leprosy because it is
better adapted to present M. leprae-derived peptide antigens
for immunosurveillance by NK cells and CD8+ T cells.
DISCUSSION
This study defines at high resolution the peptidomes of
HLA-B*46:01 and its parent allotypes. The HLA-B*46:01 pepti-
dome is restricted in the length, type, and frequency of peptides
that it presents for immunosurveillance. A minority of peptides
bound by HLA-B*46:01 and HLA-C*01:02 form ligands for the
NK cell receptor KIR2DL3. HLA-B*46:01 is significantly better
adapted than its more closely related parent HLA-B*15:01 to
bind antigenic peptides derived fromM. leprae. These distinctive
functions are consistent with amodel in which HLA-B*46:01 rose
A B C D
Figure 4. HLA-B*46:01 Has a Restricted Peptidome
(A) The information content of random subsets of N 9-mer peptides sampled from each allotype. For each value of N, this procedure was repeated 100 times and
the mean is reported.
(B) For each allotype, the proportion of total peptides contributed by the tenmost abundant peptides. Themost abundant peptide is 1. The area under each plot is
proportional to the percentage, from left to right, that the ten peptides contribute: HLA-B*15:01 (red), HLA-C*01:02 (blue), and HLA-B*46:01 (orange).
(C) Graph showing the cumulative peptide abundance (%), starting at 1 with the most abundant peptide and sequentially adding peptides of decreasing
abundance. Arrows show the number of peptides that constitute 50% of the total peptidome.
(D) Histogram comparing the diversity of each peptidome as assessed by the Shannon-Wiener (upper panel) and Simpson (lower panel) diversity indices.
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in frequency in Southeast Asia because it provides carriers with
protection from severe leprosy.
HLA-B*15:01 and HLA-B*46:01 share Ser77 and Asn80, the
residues commonly associated with the C1 epitope. However,
these residues are insufficient to confer reactivity with KIR2DL3
without HLA-C*01:02-derived Val76. We show that the interac-
tion between KIR2DL3 and HLA is dependent on the length
and sequence of the bound peptide. Consistent with previous
studies using exogenous peptide, we found that KIR recognition
of endogenously processed peptides was most sensitive to the
amino acid at position 8 and more generally to those at the C ter-
minus of the peptide, a region that corresponds to the KIR-bind-
ing site (Boyington et al., 2000). Although no structure of
KIR2DL3 in complex with its ligand has been solved, comparison
with KIR2DL2 bound to HLA-C*03:04 shows that Gln71 in the D1
domain forms a hydrogen bond with the amino acid at P8 (Boy-
ington et al., 2000). The formation of this hydrogen bond brings
Gln71, Ser184, and Glu187 of KIR2DL2 (residues that are iden-
tical in KIR2DL3) into such close proximity with the peptide
that it constrains the size of the P8 side chain that would allow
interaction with KIR. KIR2DL2 also directly contacts the amino
acid at position 7 in the peptide, which is more exposed in
this structure as compared to other HLA class I (Fan et al.,
2001). Interestingly, we identified one peptide, the nonamer
YANDFASEY, that bound KIR2DL3 despite having Glu at P8.
This finding indicates that, despite a general preference for pep-
tides with small size and low hydrophobicity and specifically for
those without Glu at P8, KIR2DL3 is able to recognize selected
peptides with these characteristics. Additional functional exper-
iments are needed to confirm this finding. Furthermore, we found
that Asn at P3 is significantly more common in KIR2DL3-permis-
sive peptides, indicating that residues outside the KIR-binding
site may also influence recognition of HLA-B*46:01 by KIR2DL3,
presumably as a result of structural constraints imposed through
the peptide backbone.
Although less stringent than the interaction between the CD8
TCR and HLA (Malnati et al., 1995), our data suggest that the
majority of peptides (>75%) presented by HLA-B*46:01 and
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Figure 5. HLA-B*46:01 Differs from HLA-B*15:01 in Its Capacity to Bind Pathogen-Derived Peptides
(A) Inverse distance weighted map (ArcGIS) showing frequency of HLA-B*46:01 in Southeast Asia. Color scale bars correspond to allele frequency categories.
Frequencies are from allelefrequencies.net (Gonza´lez-Galarza et al., 2015).
(B) Map showing the disability life-adjusted life year (DALY) for leprosy per 100,000 inhabitants of Southeast Asia (Mathers et al., 2008). Disability life-adjusted life
year is a measure of overall disease burden, expressed as the number of years lost due to disability, ill health, or early death.
(C) Plots representing the number of nonamer peptides derived fromMycobacterium leprae,Mycobacterium tuberculosis,Salmonella Enteritidis, H1N1 influenza,
and HIV-1 predicted to bind each allotype. The median of each plot is indicated with a solid black line. Red circles (HLA-B*15:01), orange squares (HLA-B*46:01),
and blue triangles (HLA-C*01:02) linked with black lines indicate the number of peptides derived from each antigenic protein predicted to bind the given allotype.
Listed below each plot is the total number of proteins and peptides investigated. Horizontal bars with associated p values (paired t tests) indicate significant
differences. Binding predictions were made using NetMHC 4.0 (Nielsen et al., 2003).
(D) Summary plot showing the percentage of pathogen-derived peptides bound by each allotype.
(E) Principal-component analysis density plot showing the distribution of nonamer peptides bound by HLA-B*46:01, divided into two clusters (HLA-C*01:02-like,
pink; B*15:01-like, orange) on the basis of a k-nearest neighbor algorithm (top panel). The distribution of M. leprae-derived peptides predicted to bind
HLA-B*46:01 (center panel, red dots) and KIR2DL3-permissive peptides bound by HLA-B*46:01 (bottom panel, red dots) is shown overlaid on the HLA-B*46:01
peptidome, with the percentage of peptides falling in each cluster shown.M. leprae-derived peptides are significantly more likely to fall in cluster 1 (Fisher’s exact
test, p = 0.0028).
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HLA-C*01:02 do not provide strong ligands for KIR2DL3. Simi-
larly, a previous study showed that KIR2DL3 recognized only a
small number of exogenous peptides bound by HLA-C*08:02
(Sim et al., 2017). This specificity may explain why KIR2DL3
binding to C1 appears weaker than that of KIR2DL2 to C1 or
KIR2DL1 to C2 (Hilton et al., 2012, 2015a; Moesta et al., 2008).
A second implication of this specificity is that the system may
be usurped by pathogens. Supporting this possibility, previous
studies have shown that HIV produces escape mutants (Alter
et al., 2011; Ho¨lzemer et al., 2015). One example is a mutation
in the p24 Gag epitope that enabled significantly better binding
of KIR2DL3 to HLA-C*03:04-expressing cells presenting the
variant epitope (Ho¨lzemer et al., 2015). Antagonism of NK cell
function by peptides with weak affinity for KIR is likely to be
another functional consequence of KIR2DL3 peptide selectivity.
Although the specificmolecular mechanisms that underlie the ef-
fect are unclear, peptides with weak affinity for inhibitory KIR
antagonize those with high affinity, preventing inhibitory synapse
formation and reducing the inhibitory signaling potential of NK
cells (Borhis et al., 2013; Fadda et al., 2010). Previous estimates
indicate 30% of HLA-C*01:02-bound peptides provide strong
ligands for KIR2DL2 and 2DL3 (Fadda et al., 2010). We find
that only 7% of HLA-C*01:02-bound peptides and 21%
of HLA-B*46:01-bound peptides provide strong ligands for
KIR2DL3, suggesting that peptide antagonism may play a
greater functional role than previously recognized.
The HLA-B*46:01 peptidome is smaller and less diverse than
that of HLA-B*15:01, its more closely related parent. This loss
of diversity may result from reduced plasticity of the HLA-
C*01:02-derived a1 helix segment that restricts the range of
permissible peptides (Sibilio et al., 2005, 2008). A basic patch
comprising R62, K66, and R69may contribute further restriction.
These residues likely contribute to the shared preference of HLA-
C*01:02 and HLA-B*46:01 for acidic residues at position 4 and
the additional length and frequency constraints that differentiate
these allotypes from HLA-B*15:01 (Barber et al., 1996).
In addition to its effect on the plasticity of the peptide-binding
groove, the HLA-C*01:02-derived a1 helix segment contains the
KYRV motif, which reduces cell-surface expression of HLA-C
relative to HLA-A and -B (Sibilio et al., 2008). Although the cell-
surface expression of HLA-B*46:01 has not specifically been
studied, it is known to have increased intracellular retention
due to prolonged association with HLA-dedicated chaperones
(Sibilio et al., 2008). Thus, HLA-B*46:01 likely combines low-
cell-surface expression with a low-diversity peptidome. By
contrast, several studies have demonstrated an inverse correla-
tion between cell-surface expression and peptidome diversity
(Chappell et al., 2015; Tregaskes et al., 2016). First described
in the chicken MHC, an initial survey of four HLA-B allotypes
shows a similar correlation, suggesting it is a broadly conserved
feature (Chappell et al., 2015). Thus, HLA-B*46:01 appears an
outlier in this regard and more characteristic of HLA-C than
HLA-B. The relationship between cell-surface expression and
peptidome diversity within HLA-C has not been extensively stud-
ied, although HLA-C allotypes are known to exhibit differential
cell-surface expression (Apps et al., 2013).
Comparative studies have shown that MHC class I with
restricted peptidomes confer protection against one or several
closely related pathogens, whereas those with more diverse
peptidomes confer broader disease resistance (Chappell et al.,
2015; Tregaskes et al., 2016). In the former category,
HLA-B*46:01 may permit prioritization of peptides from a spe-
cific pathogen, allowing an individual to mount an effective im-
mune response. One candidate pathogen is M. leprae that
causes leprosy, a chronic granulomatous infection of the skin
and peripheral nerves. Leprosy emerged as a major infectious
disease in the last 50,000 years as modern humans expanded
outward across the globe from Africa (Monot et al., 2005). Infec-
tion rates likely peaked with the massmovement of people along
trade routes between Africa and Asia prior to the advent of mod-
ern medicine (Karlsson et al., 2014). Leprosy is still common in
many tropical regions, Southeast Asia being a notable hotbed
of the disease (Reibel et al., 2015). Leprosy has exerted strong
selective pressure on the human genome in general (Karlsson
et al., 2014) and on the HLA region in particular (Chan, 1983;
Franceschi et al., 2011; Shankarkumar, 2004; Shankarkumar
et al., 2003; Takata et al., 1978; Zhang et al., 2009).
Epidemiologic studies show that carriers of the HLA-B*46:01-
MICA-A5 haplotype are protected against the development of
lepromatous leprosy, the fulminant, life-threatening form of the
disease (Wang et al., 1999). Consistent with this finding, we
show that HLA-B*46:01 is predicted to bind a significantly higher
number of antigenic peptides derived from M. leprae than its
parent allotype HLA-B*15:01 and a similar number to that bound
by HLA-C*01:02. BecauseHLA-B*46:01 andHLA-C*01:02 are in
strong linkage disequilibrium (Abi-Rached et al., 2010), the result
is that HLA-B*46:01 carriers would have at least two HLA class I
loci able to effectively present M. leprae-derived peptides.
Presentation of M. leprae peptides to the TCR and KIR cells is
likely to result in a strong cell-mediated immune response, which
is amajor determining factor in the clinical progression of leprosy
(Kaleab et al., 1995; Ridley, 1974). Supporting a role for KIR-
mediated immunity in the outcome ofM. leprae infection, studies
show that patients with the less severe tuberculoid form of
leprosy have increased frequencies of activating KIR2DS2 and
KIR2DS3 (Franceschi et al., 2008). Together these findings
support the hypothesis that HLA-B*46:01 rose in frequency
because it confers protection against severe infection caused
by M. leprae.
Arguing against this mechanism is our finding that both
HLA-B*46:01 and HLA-C*01:02 present a higher number of pep-
tides derived from M. tuberculosis. In contrast to leprosy, an
epidemiologic study shows that HLA-B*46:01 carriers are more
susceptible to pulmonary tuberculosis (Chandanayingyong
et al., 1988). Although this study was small (only 36 subjects)
and susceptibility was also linked to HLA class II, it suggests
that the number of pathogen-derived peptides bound by a given
allotypemay not be the dominant mechanism that promotes dis-
ease resistance.
Intense reactivity against pathogens and a lack of collateral
reactivity to self are critical features of a successful immune sys-
tem. HLA-B*46:01 appears able to succeed in the first require-
ment (although apparently with a narrow remit as epidemiologic
studies show it confers susceptibility to tuberculosis, malaria,
HIV, and SARS coronavirus; Chandanayingyong et al., 1988;
Hananantachai et al., 2005; Huang et al., 2009; Lin et al.,
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2003). However, several studies suggest that it falls short in the
second, predisposing individuals to autoimmune conditions,
including myasthenia gravis (Chan et al., 1993) and Graves dis-
ease (Chan et al., 1978; Hawkins et al., 1985; Naito et al., 1987),
as well as to nasopharyngeal carcinoma (Chan et al., 1983).
The apparent predisposition to self-reactivitymayoccur because
of reduced TCR diversity (a likely result of its low-diversity pepti-
dome), increased NK cell reactivity, or an as yet undiscovered
mechanism. However, these data support the notion that there
is an immunological trade-off between protection against infec-
tious disease and protection against self-reactivity. Intriguingly,
this hypothesis is consistent with the clinical observation that
patients with psoriasis, an autoimmune skin condition, are pro-
tected from thedevelopment of leprosy (Dogra et al., 2003;Hens-
eler and Christophers, 1995; Wahba et al., 1980).
EXPERIMENTAL PROCEDURES
Further details are given in the Supplemental Experimental Procedures.
Isolation of HLA Class I Complexes from 721.221 Cells
Isolation and analysis of peptides were performed as previously described
(McMurtrey et al., 2016; Trolle et al., 2016; Yaciuk et al., 2014). Briefly,
721.221 cells, which lack endogenous HLA class I expression, were trans-
fected with constructs encoding soluble forms (sHLA) of HLA-B*15:01,
HLA-B*46:01, and HLA-C*01:02. sHLA binds a similar peptide repertoire to
membrane-associated HLA class I (Scull et al., 2012). The sHLA-peptide com-
plexes were affinity purified from the cell supernatant on an anti-W6/32
Sepharose column, eluted, and the bound peptides dissociated from the
HLA by denaturation in 10% acetic acid for 15 min at 75C. Peptides were
separated from the denatured proteins by passage through a stirred cell ultra-
filtration device (3-kDa-cutoff membrane [Millipore]). The peptide-containing
filtrate was lyophilized, re-suspended in 10% acetic acid, and separated into
40 fractions by reverse-phase high-performance liquid chromatography
(HPLC) as described (Trolle et al., 2016). Each fraction was dried and re-sus-
pended in 10% acetic acid for liquid chromatography-mass spectrometry
(LC-MS). Approximately 25% of each HPLC fraction was injected into a
nano-scale reverse-phase liquid chromatography Eksigent nano-LC-4000
(Sciex) system. Column specifications, mobile phase solvents, and the elution
gradient were as described (Trolle et al., 2016). Eluted fractions were ionized
using a NanoSpray III (Sciex) ion source into a Sciex TripleTOF 5600 mass
spectrometer.
Isolation and Analysis of KIR-Permissive Peptide Ligands from
721.221 Cells
Biotinylated KIR2DL3 monomer was incubated with streptavidin-coated
microbeads (Thermo Fisher Scientific), according to the manufacturer’s in-
structions, and washed to remove excess KIR2DL3. Then 300 ml containing
75 mgW6/32-purified sHLA-B*15:01, sHLA-C*01:02, and sHLA-B*46:01mate-
rial was divided into three equal aliquots each and incubated for 16 hr at 4C
with KIR2DL3-conjugated microbeads, unconjugated blank beads, or no
beads. KIR2DL3-conjugated beads were added in 3.5 molar excess of
KIR2DL3 to sHLA. Following incubation, each 25-mg aliquot was washed
with 30 bead volumes, and ligand identification was performed in data-inde-
pendent mode (DIA) in triplicate.
NK Cell Cytotoxicity Assay Using T2 Cell Lines
To test the effect of specific peptides, T2 cells were incubated in serum-free
RPMI media overnight at 26C in the presence of 100 mM synthetic peptide
(GenScript). Cells were washed and stained with the HLA-C-specific DT9 anti-
body (EMDMillipore). Peptide stabilization was assessed by flow cytometry on
an Accuri C6 benchtop flow cytometer (BD Biosciences).
NK cells were isolated from five healthy KIR A haplotype andHLA-C1 homo-
zygous donors, and they were stimulated overnight with 500 units/mL recom-
binant human IL-2 (R&D Systems) in RPMI 10% complete media. T2 cells
(3 3 104) were incubated with 100 mM peptide (Genscript) overnight in
serum-free media at 26C, washed, and re-suspended in serum-free media
with anti-CD107a-TexasRed antibody (eBioscience). T2 cells were incubated
with NK cells at a target:effector ratio of 10:1 for 3.5 hr in serum-freemedia with
500 units/mL recombinant human IL-2. Surface staining was performed using
anti-KIR2DL2/3-APC GL183 (Beckman Coulter) and anti-KIR3DL1-FITC DX9
(BioLegend) to identify KIR2DL3+/KIR3DL1NK cells. Following surface stain-
ing, cells were treated with live/dead orange (Life Sciences) and fixed (Cytofix,
BDBiosciences). Cells were analyzed on an LSR II cytometer (BDBiosciences)
at the Stanford Flow Cytometry Core Facility. A representative gating strategy
is shown in Figure S5B.
Statistical and Bioinformatic Methods
Calculation of Peptidome Sequence Similarity
The information content for each peptidome was calculated as the summed
Kullback-Leibler distance (KLD) over the positions in the binding motif.
A random subset of N 9-mer peptides was sampled from each allotype, and
amino acids frequencies (paa) were estimated using sequence weighting and
pseudo counts correction for a low number of observations, as previously
described (Nielsen et al., 2004). The KLD at each position was calculated as
sum 2* paa * log2(paa/qaa), where qaa is the background frequency of amino
acid (aa). For each value of N, this procedure was repeated 100 times and
the mean is reported.
Covariation Analysis
To search for covariation between peptide positions, coupling terms were
calculated as described (Lockless and Ranganathan, 1999) and plotted as
a heatmaps, processed and analyzed with custom Perl and MATLAB
(MathWorks) scripts as described (Mendoza et al., 2012). Scripts are available
upon request.
PCA
For each amino acid in a peptide, four biochemical properties (molecular
weight, hydropathy index, surface area, and isoelectric point) weredetermined.
Thus, 36 variablesweregenerated for eachnonamerpeptide.AcustomRscript
(available at www.stanford.edu/group/parhamlab/software) was used to
generate PCA plots for nonamer peptides from the three HLA class I allotypes.
The k-nearest neighbor algorithm (k=15) (Venables andRipley, 2002)was used
to cluster the HLA-B*46:01 peptidome by similarity to those of HLA-B*15:01
and HLA-C*01:02. Comparison of the distribution of empirically determined
HLA-B*46:01 peptides to either M. leprae-derived peptides predicted to bind
HLA-B*46:01 or HLA-B*46:01 KIR-permissive peptides was made using a
Fisher’s exact test.
Analysis of KIR-Permissive versus Non-permissive Peptides
Fisher’s exact (specific amino acids) and two sample t tests (concatenated
properties) were used to determine the magnitude of frequency changes at
each position of the peptide between KIR-permissive and non-permissive
groups.
NK Cell Degranulation Assay
One-way ANOVA tests with multiple comparisons were used to quantify
the magnitude of changes in NK cell degranulation (percentage CD107a
expression) between KIR-permissive and non-permissive peptides bound by
HLA-C*01:02.
Prediction of Pathogen-Derived Peptide Binding to HLA-B*15:01,
HLA-B*46:01, and HLA-C*01:02
A literature search identified a set of antigenic proteins derived from five path-
ogens: M. leprae (taken from Table 2 in Wiker et al., 2011), M. tuberculosis
(taken from Table 1 in Ma˚len et al., 2008), S. Enteritidis (taken from Table 3
in Cho et al., 2015), and the complete proteome of HIV-1 (Doherty et al.,
2005) and H1N1 influenza A, strain PR1934 (NIAID Influenza Genome
Sequencing Consortium, www.fludb.org). A nine-amino acid-sliding window
was used to create a library of all possible nonamer peptides from each pro-
tein, and their binding to each allotype was predicted with NetMHC 4.0 (Niel-
sen et al., 2003). Themodel used tomake these predictions was trained on 436
nonamer peptides and 2,180 random natural negative nonamer peptides using
the NNAlign method (Andreatta et al., 2011). Percentile rank scores were esti-
mated from the distribution of prediction scores of 100,000 random natural
9-mer peptides. Peptides were considered to bind if their predicted percentile
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score was%2%. Paired t tests were used to compare the number of peptides
bound by HLA pairs.
All statistical calculations were performed in GraphPad Prism 6.0 with
a = 0.05.
SUPPLEMENTAL INFORMATION
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